CH698539A8 - Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. - Google Patents

Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. Download PDF

Info

Publication number
CH698539A8
CH698539A8 CH00249/06A CH2492006A CH698539A8 CH 698539 A8 CH698539 A8 CH 698539A8 CH 00249/06 A CH00249/06 A CH 00249/06A CH 2492006 A CH2492006 A CH 2492006A CH 698539 A8 CH698539 A8 CH 698539A8
Authority
CH
Switzerland
Prior art keywords
fatty acid
preparation
treatment
multiple sclerosis
medicaments
Prior art date
Application number
CH00249/06A
Other languages
German (de)
English (en)
Other versions
CH698539B1 (de
Inventor
Laurence S Harbige
Michael Leach
Mohammed Sharief
Paul Barraclough
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0319358A external-priority patent/GB0319358D0/en
Priority claimed from GB0410846A external-priority patent/GB0410846D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of CH698539B1 publication Critical patent/CH698539B1/de
Publication of CH698539A8 publication Critical patent/CH698539A8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CH00249/06A 2003-08-18 2004-08-13 Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. CH698539A8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0319358A GB0319358D0 (en) 2003-08-18 2003-08-18 Treatment of neurodegenerative conditions
GB0410846A GB0410846D0 (en) 2004-05-14 2004-05-14 Treatment of neurodegenerative conditions
PCT/GB2004/003524 WO2005018632A1 (en) 2003-08-18 2004-08-13 Treatment of neurodegenerative conditions

Publications (2)

Publication Number Publication Date
CH698539B1 CH698539B1 (de) 2009-08-31
CH698539A8 true CH698539A8 (de) 2009-10-15

Family

ID=34219616

Family Applications (1)

Application Number Title Priority Date Filing Date
CH00249/06A CH698539A8 (de) 2003-08-18 2004-08-13 Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose.

Country Status (13)

Country Link
US (4) US7964641B2 (https=)
EP (2) EP1660071A1 (https=)
JP (1) JP2007502805A (https=)
AU (1) AU2004266480B2 (https=)
CA (1) CA2534202C (https=)
CH (1) CH698539A8 (https=)
DE (1) DE112004001520B4 (https=)
ES (1) ES2304094B2 (https=)
FI (1) FI20060154A7 (https=)
GB (1) GB2422373B (https=)
IS (1) IS8246A (https=)
NO (1) NO20061232L (https=)
WO (1) WO2005018632A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070112592A1 (en) 2005-11-17 2007-05-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Payments in providing assistance related to health
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20080004909A1 (en) * 2005-11-30 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems related to nutraceuticals
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
EP2098229A4 (en) * 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
PL2144618T5 (pl) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2331679B1 (en) * 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Ischemic tissue cell therapy
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
EP2409695B1 (en) * 2010-07-05 2018-03-21 Beth Israel Deaconess Medical Center, Inc. Sn-2-monoacylglycerols and lipid malabsorption
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
JP2016023163A (ja) * 2014-07-22 2016-02-08 出光興産株式会社 γ−リノレン酸を含む神経細胞の酸化ストレス軽減剤
ES2937960T5 (en) 2015-02-11 2026-02-16 Aker Biomarine Human Ingredients As Lipid extraction processes
EP3256553A2 (en) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipid compositions
CN105468156A (zh) * 2015-11-25 2016-04-06 新乡医学院 一种基于α波控制的新型异步脑-机接口系统
MX2018015188A (es) 2016-06-08 2019-08-21 Sunregen Healthcare Ag Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional.
KR102054401B1 (ko) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제
CN113164377A (zh) * 2018-10-18 2021-07-23 Ds生物制药有限公司 用于治疗炎性、纤维化和增生性病状的dgla和/或15-hetre

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077371A (en) 1937-04-13 Synthetic drx
US655579A (en) * 1900-02-27 1900-08-07 Draper Co Lease-forming mechanism.
US2617791A (en) 1949-09-15 1952-11-11 Trojan Powder Co Recovery of valuable products from pentaerythritol mother liquor
US3158541A (en) 1959-12-18 1964-11-24 Escambia Chem Corp Product for reduction of blood cholesterol concentration
US3082228A (en) 1959-12-18 1963-03-19 Escambia Chem Corp Method for producing monoesters of polyunsaturated fatty acids
IE32979B1 (en) 1968-03-07 1974-02-06 Unilever Ltd Spreadable fats
US3558656A (en) 1968-04-19 1971-01-26 Smith Kline French Lab Glycerol trichloroethyl carbonate and derivatives
US3671563A (en) 1968-04-19 1972-06-20 Smith Kline French Lab Glycerol 3-(2,2,2-trichloroethyl) carbonate
US3676472A (en) 1969-07-28 1972-07-11 American Home Prod Certain linoleic and linolenic acid ester fractions of vegetable oils and derivatives thereof
US3748348A (en) 1970-07-27 1973-07-24 Lever Brothers Ltd Directed-interesterified glyceridic oils having a high linoleic acid content and process for their production
US3671557A (en) 1970-09-17 1972-06-20 Smith Kline French Lab 1,2-diacylglycerol 3-(2,2,2-trichloroethyl) carbonates
GB1370021A (en) 1971-03-25 1974-10-09 Unilever Ltd Process for preparing usaturated carboxylic acids
US3855254A (en) 1972-03-31 1974-12-17 Lever Brothers Ltd Interesterification process
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
US3988446A (en) 1974-11-07 1976-10-26 Abbott Laboratories Glycerides with anti-inflammatory properties
US3972907A (en) 1975-03-24 1976-08-03 G. D. Searle & Co. Anti-hyperlipidemic fatty acids and esters
US4048202A (en) 1975-04-11 1977-09-13 G. D. Searle & Co. 3-O-Alkanoylglyceric acids
US4178299A (en) 1978-03-27 1979-12-11 Abbott Laboratories Process for preparing 1,3-diacyl glycerols
DE2967049D1 (en) * 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4181670A (en) 1978-12-11 1980-01-01 G. D. Searle & Co. Phenyl 5Z,8Z,11Z,14Z-eicosatetraenoate and congeners
EP0092076B1 (fr) 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Composition lipidique destinée à l'alimentation orale, entérale ou parentérale
US4607052A (en) * 1983-04-15 1986-08-19 Roussel-Uclaf Triglycerides, dietetic and therapeutical applications and compositions containing them
US4701468A (en) * 1983-04-15 1987-10-20 Roussel-Uclaf Oxidized triglycerides having therapeutic utility
US4701469A (en) * 1983-04-15 1987-10-20 Roussel Uclaf Triglycerides, process for therapeutical applications and compositions containing them
GB8404463D0 (en) 1984-02-21 1984-03-28 Efamol Ltd Microbiological production of essential fatty acids
AT383130B (de) * 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
US5077312A (en) 1984-07-08 1991-12-31 Oncogen Biologically active lipids binding membrane receptors
GB2178752B (en) 1985-07-12 1989-10-11 Unilever Plc Substitute milk fat
US4888324A (en) 1985-10-01 1989-12-19 Angio-Medical Corporation Method for enhancing angiogenesis with lipid containing molecules
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5151291A (en) 1985-12-27 1992-09-29 Nisshin Flour Milling Co., Ltd. Glycerides of eicosapentaenoic acid, processes for preparing the same and oil and fat products containing the same
US5306730A (en) 1986-02-03 1994-04-26 Kabushiki Kaisha Yakult Honsha Botulinum toxin neutralizer
US5227403A (en) 1986-10-01 1993-07-13 The Nisshin Oil Mills, Ltd. Fats and oils having superior digestibility and absorptivity
US4867965A (en) 1986-10-02 1989-09-19 Revlon, Inc. Fatty acid diesters
FR2617161B1 (fr) 1987-06-29 1989-10-27 Azar Robert Nouveaux glycerides d'acide gras insature et leur procede d'obtention
US4832975A (en) 1987-09-29 1989-05-23 The Procter & Gamble Company Tailored triglycerides having improved autoignition characteristics
DK565288D0 (da) * 1988-10-11 1988-10-11 Novo Industri As Fremgangsmaade til fremstilling af triglycerider, anvendelse af saadanne triglycerider og en emulsion, der indeholder saadanne triglycerider
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
US5922345A (en) 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
GB9026648D0 (en) 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
PH11992043811B1 (en) 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
JPH04328199A (ja) 1991-04-26 1992-11-17 Nisshin Oil Mills Ltd:The α−リノレン酸高含有トリグリセライドの濃縮方法
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
US5674901A (en) 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
JPH05310638A (ja) 1992-05-01 1993-11-22 Idemitsu Petrochem Co Ltd 不飽和脂肪酸トリグリセライドの製造法
JPH06172263A (ja) 1992-08-14 1994-06-21 Agency Of Ind Science & Technol 高純度アラキドン酸トリグリセリド及びその製造方法
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
CA2151820C (en) 1993-01-15 2000-11-28 Stephen Joseph Demichele Structured lipids
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
JPH0741421A (ja) 1993-05-28 1995-02-10 Suntory Ltd ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤
US20050027004A1 (en) 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5663450A (en) 1993-08-17 1997-09-02 Cv Therapeutics Macrophage lipid chemoattractant
US5668174A (en) 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
JPH07309773A (ja) 1994-05-16 1995-11-28 Sagami Chem Res Center アセチルコリン放出促進剤
FR2722410B1 (fr) 1994-07-15 1996-10-04 Grinda Jean Robert Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
JP3770628B2 (ja) 1994-08-09 2006-04-26 サントリー株式会社 遅延型アレルギー反応を介する医学的症状の予防及び改善剤
EP0707850A1 (en) 1994-09-21 1996-04-24 Scotia Holdings Plc Use of polyunsaturated fatty acids for the manufacture of a medicament for the treatment of brest pain
EP0711503A3 (en) 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5990163A (en) 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
US6410078B1 (en) 1995-04-28 2002-06-25 Loders-Croklaan B.V. Triglycerides, rich in polyunsaturated fatty acids
DE69633818T2 (de) 1995-08-07 2005-12-08 Suntory Ltd. Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US6015798A (en) 1995-10-10 2000-01-18 Colgate Palmolive Company Method for reducing the damaging effects of radiation therapy on animal skin and mucosa
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
WO1997038688A1 (en) 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6340485B1 (en) 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
CA2271166C (en) 1996-06-03 2006-08-29 Croda International Plc Compositions and uses thereof
CA2259330C (en) 1996-06-29 2003-03-18 The Scottish Agricultural College Improvement of male fertility with antioxidants and/or polyunsaturated fatty acids
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
CN1109543C (zh) 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
EP1039892B1 (en) 1997-02-21 2004-04-28 Abbott Laboratories Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
US6201022B1 (en) 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US5968809A (en) 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US6051754A (en) 1997-04-11 2000-04-18 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
US6432684B1 (en) 1997-04-11 2002-08-13 Abbott Laboratories Human desaturase gene and uses thereof
US20020037876A1 (en) 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6369252B1 (en) * 1998-02-26 2002-04-09 The University Of Georgia Research Foundation, Inc. Structured lipids
AU765670B2 (en) 1998-04-03 2003-09-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic endogenous cannabinoids analogues and uses thereof
US6214372B1 (en) 1998-05-04 2001-04-10 Con Lin Co., Inc. Method of using isomer enriched conjugated linoleic acid compositions
US7101914B2 (en) 1998-05-04 2006-09-05 Natural Asa Isomer enriched conjugated linoleic acid compositions
US6696584B2 (en) 1998-05-04 2004-02-24 Natural Asa Isomer enriched conjugated linoleic acid compositions
CN1219064C (zh) 1998-08-04 2005-09-14 嘉吉有限公司 植物脂肪酸去饱和酶启动子
KR100325581B1 (ko) 1998-08-07 2002-08-24 오우택 아라키토닉산의리폭시게네이즈대사결과물질을함유하는진통제용조성물
US6555579B2 (en) 1998-08-13 2003-04-29 The Wistar Institute Methods for reducing atherosclerotic plaques
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP3779505B2 (ja) 1999-08-24 2006-05-31 花王株式会社 油脂組成物
US6426367B1 (en) 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6340705B1 (en) 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
DE60027376T2 (de) 1999-09-30 2007-02-01 Loders Croklaan B.V. Zusammensetzungen, enthaltend Pinolensäure sowie deren Verwendung zur Gesundheitserhaltung
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20010047036A1 (en) 1999-12-17 2001-11-29 Vanderhoof Jon A. Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US6361806B1 (en) 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
ES2213666T3 (es) 2000-02-24 2004-09-01 Unilever N.V. Acido pinolenico contra la diabetes.
JP2003535892A (ja) 2000-06-23 2003-12-02 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム ２−アラキドニルグリセロール（２−ＡＧ）−腫瘍壊死因子−αの阻害剤および閉鎖性頭部損傷における脳の神経保護因子
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002047176A (ja) 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2815227B1 (fr) 2000-10-17 2003-04-11 Schwartz Laboratoires Robert Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels
NO310176B1 (no) 2000-11-13 2001-06-05 Wadlund As Sammensetning for hud som inneholder kitosan-konjugert CLA og kitosankonjugert vitamin A eller et <beta>-cyklodekstrin-konjugertvitamin A samt fremgangsmåte for fremstilling og anvendelse avdenne
US6528040B1 (en) 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
CA2439293A1 (en) 2001-03-05 2002-09-12 Stephen P. Ernest Enteral formulation
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
WO2003004667A1 (en) * 2001-07-02 2003-01-16 Suntory Limited Process for producing fat comprising triglyceride containing highly unsaturated fatty acid
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1285590A1 (en) 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
AU784852B2 (en) 2001-08-10 2006-07-06 Mars, Incorporated Canine support diet
US20030032674A1 (en) * 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6677470B2 (en) 2001-11-20 2004-01-13 Natural Asa Functional acylglycerides
ITMI20012732A1 (it) 2001-12-20 2003-06-20 Health Pharma S R L Integratore alimentare per neuropatici
AUPS082102A0 (en) 2002-03-01 2002-03-21 Women's And Children's Hospital Therapeutic properties of oils
NZ535549A (en) 2002-03-08 2006-02-24 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
US20040048926A1 (en) 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
WO2003097034A1 (en) 2002-05-17 2003-11-27 Nikken Chemicals Co., Ltd. TGF-α EXPRESSION INHIBITORS
US7335481B2 (en) 2002-07-24 2008-02-26 Christer Owman Methods of identifying compounds that affect a fatty acid cell-surface receptor
WO2004098570A1 (en) 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US7074418B2 (en) 2002-11-18 2006-07-11 Changaris David G Conjugated fatty acid based emulsion and methods for preparing and using same
US20040229950A1 (en) 2002-11-26 2004-11-18 Vanderhoek Jack Y. Method and composition with conjugated linoleic acid esters
US6841573B2 (en) 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US20040209953A1 (en) * 2002-12-06 2004-10-21 Wai Lee Theresa Siu-Ling Glyceride compositions and methods of making and using same
US20040208939A1 (en) 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
AU2004260702A1 (en) * 2003-08-01 2005-02-10 Ability Biomedical Corporation Combination therapies for Multiple Sclerosis
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators

Also Published As

Publication number Publication date
US20080194684A1 (en) 2008-08-14
CA2534202A1 (en) 2005-03-03
AU2004266480A1 (en) 2005-03-03
JP2007502805A (ja) 2007-02-15
CH698539B1 (de) 2009-08-31
US20120142775A1 (en) 2012-06-07
AU2004266480B2 (en) 2011-03-03
GB2422373B (en) 2008-05-21
EP2324828A1 (en) 2011-05-25
GB2422373A (en) 2006-07-26
WO2005018632A1 (en) 2005-03-03
EP1660071A1 (en) 2006-05-31
DE112004001520B4 (de) 2008-04-10
ES2304094A1 (es) 2008-09-01
CA2534202C (en) 2012-01-17
DE112004001520T5 (de) 2006-07-06
US7964641B2 (en) 2011-06-21
IS8246A (is) 2006-01-19
FI20060154A7 (fi) 2006-05-11
GB0603646D0 (en) 2006-04-05
FI20060154L (fi) 2006-02-17
NO20061232L (no) 2006-05-15
US20100113810A1 (en) 2010-05-06
ES2304094B2 (es) 2010-10-14
US20100113595A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
CH698539A8 (de) Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose.
PH12021550328A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
DE69401498D1 (de) Backfette und diese enthaltenden teige
JP2016508158A5 (https=)
RU2002133234A (ru) Косметические средства, содержащие производные 2-фуранона
BRPI0518398A2 (pt) Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
CA1310911C (en) Essential fatty acid compositions
ATE318133T1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
EP1732548A4 (en) METHOD OF USE OF AMINOPYRINE COMPOSITION WITH DELAYED RELEASE
DE69830586D1 (de) Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
BR112017027909A2 (pt) composição, e, uso de uma composição
Lane Occupational Dermatitis in Dentists: Susceptibility to Procain
IT966375B (it) Composizione di esteri di acido grasso con olio insaturi come succedaneo dell olio di spermaceti e suo procedimento di spermaceti e suo procedimento di impiego nel trattamento di pelle o cuoio
RS62825B1 (sr) Tirotricin za upotrebu u lečenju ili profilaksi telesnih mirisa i preparati za to
RU2011152276A (ru) Моноэфиры и диэфиры аскорбиновой кислоты с ненасыщенными жирными кислотами и их косметическое применение
MX2023006727A (es) Esteres de acidos dicarboxilicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d.
IL97271A0 (en) Pharmaceutical compositions having depigmentating and antiphotoageing activity
EP0036652A3 (de) Cephalosporinderivate, entsprechende Präparate, die Verwendung dieser Produkte bei der Behandlung von Krankheiten, die Herstellung der Wirkstoffe sowie dabei anfallende Zwischenprodukte
MX2021002398A (es) Una composicion que contiene hierro y uso de la misma.
Krol et al. Infant and maternal engagement: A coding rubric for infant-mother free play analysis
LEWIS et al. LICHEN PLANUS OF THE NAIL BED: REPORT OF A CASE
Mikheyev et al. A rare presentation of palmoplantar lichen planus

Legal Events

Date Code Title Description
PK Correction

Free format text: BERICHTIGUNG ERFINDER

PL Patent ceased